AZD-2066

AZD-2066 is a small molecule investigational drug developed by AstraZeneca. It acts as an antagonist of the metabotropic glutamate receptor 5 (mGluR5), a G-protein coupled receptor involved in synaptic plasticity and modulation of neural network activity. The drug was developed for oral administration and investigated primarily for the treatment of pain indications such as chronic neuropathic pain, painful diabetic neuropathy, depressive disorders, and gastro-oesophageal reflux disease. Clinical development included phase II trials for diabetic neuropathic pain and phase I trials for gastroesophageal reflux disease; however, all research on this compound has been discontinued[1][4][5].

Other names

Pyridine, 4-(5-((1r)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4h-1,2,4-triazol-3-yl)